Mitral regurgitation (MR) is one of the most common valvular heart disease (VHD) lesions observed in Western populations.
Cross-Sectional Imaging in the Evaluation of Mitral Regurgitation
Mitral regurgitation (MR) is one of the most common valvular heart disease (VHD) lesions observed in Western populations. 1 MR is typically classified as primary (degenerative) when a pathological abnormality of ≥1 components of the mitral valve apparatus leads to valvular incompetence, most commonly mitral valve prolapse (MVP), or secondary (functional) when MR occurs in the setting of left ventricular (LV) remodeling (dilatation and/or global or regional dysfunction) that results in failure of leaflet coaptation without a primary abnormality of the mitral valve apparatus. 2 Surgical intervention is recommended in patients with severe primary MR in the presence of symptoms and/or evidence of LV decompensation from volume overload (ie, LV ejection fraction 30% to 60% and/or LV systolic diameter ≥40 mm). 2 In the absence of these features, mitral valve surgery should still be considered in patients with severe degenerative MR if there is a high likelihood of successful repair and low risk of operative mortality. Preoperative imaging is, therefore, helpful to guide decisions on the timing of surgery in patients with MR by providing an accurate assessment of its hemodynamic severity and mechanism and the extent of secondary LV remodeling. For patients with severe MR who are deemed to be at too high risk for surgery because of significant comorbidities, transcatheter mitral valve interventions are emerging as an alternative therapy and are being increasingly adopted in clinical practice. In this setting, preprocedural imaging has an additional role in providing information about the suitability of such an approach, the likelihood of success and risk of complications associated with device-specific transcatheter therapies.
Two-dimensional (2D) echocardiography is the firstline imaging modality used in the evaluation of patients with suspected MR. 2D echocardiography is important not only in the assessment of MR mechanism and severity but also in quantifying the hemodynamic consequences of MR as determined by LV size and function, left atrial size, pulmonary artery pressure, and right ventricular (RV) size and function. 2, 3 Three-dimensional (3D) echocardiography, in particular transesophageal echocardiography, enhances the granular anatomic evaluation of the mitral valve apparatus, MR mechanism(s), and quantification of MR severity. 4 3D transesophageal echocardiography is also fundamental for the guidance of transcatheter mitral valve procedures 5 and in particular for transcatheter mitral valve replacement (TMVR). 6 In patients with secondary MR, LV morphological changes related to the underlying cardiomyopathy can create structural changes resulting in incomplete leaflet coaptation. Investigation of coronary artery disease severity with either invasive coronary angiography or coronary CT angiography and the extent of myocardial ischemia, scar burden, and viability using other imaging methods such as nuclear perfusion scanning or CMR are commonly used in clinical practice in these patients.
Recent VHD guidelines also recognize the importance of advanced cardiovascular cross-sectional imaging (cardiac CT and CMR). These methods are important clinical tools for the diagnosis and quantification of VHD severity in patients with suboptimal echocardiographic views, when there is uncertainty or disagreement between modalities, and for planning transcatheter interventions. CT provides a comprehensive anatomic 3D data set for the evaluation of the mitral valve complex and morphological abnormalities. CMR adds important prognostic information through accurate estimation of MR severity and also by evaluating the degree of LV remodeling. The following discussion reviews the role of CMR in the assessment of MR severity and LV remodeling and the role of CT in morphological evaluation of the mitral valvular apparatus with a focus on its role in TMVR planning.
Cardiac MRI for the Assessment of Mitral Regurgitation Severity
VHD management guidelines recommend a multiparametric echocardiographic approach for the evaluation of MR severity. 2, 3 Recently, there has been growing interest in the incremental role of CMR in evaluating mitral valve disease. Although there are some data on its role in the evaluation of rheumatic mitral stenosis, 7, 8 its incremental value has been in the evaluation of MR severity and the ability to predict outcomes after mitral valve interventions. Although some studies suggest that MR can be reliably assessed subjectively using cine steady-state free precession images, [9] [10] [11] the level of agreement with echocardiography or invasive cine angiography is modest. 12 The primary advantage of CMR is in its ability to calculate MR volume and fraction using 1 of 3 quantitative methods:
1. Planimetered LV stroke volume (SV) minus aortic forward SV by phase contrast. 2. Mitral valve inflow by phase contrast minus forward aortic SV by phase contrast. 3. Planimetered LV SV minus planimetered RV SV in the absence of other valvular regurgitation. The mitral regurgitant fraction using any of the above methods is calculated as: (MR volume/LV SV)×100%. CMR has an advantage compared with echo primarily because of its ability to quantify MR severity without being affected by MR jet shape or direction. This was highlighted recently in a study of patients treated with MitraClip (Abbott Vascular, Menlo Park, CA), where the assessment of residual MR may be difficult because of multiple eccentric jets. CMR performed well in the quantification of MR severity with greater reproducibility compared with echo. 13 Conversely, CMR quantification can also have some challenges with erroneous flow assessment because of phase offset errors, which can occur in the presence of local eddy currents. Generally, flow-based CMR methods are more reproducible than volumetric methods and allow correction for additional valvular lesions.
14 MR volumes are larger using the standard indirect method (planimetered LV SV−aortic forward SV by phase contrast) with more patients meeting MR volume and MR fraction thresholds (≥60 mL and ≥50%, respectively) using this method among those referred for mitral valve surgery. 15 It is also worth noting that cardiac arrhythmias, which are often present in patients with MR, can affect image quality and MR quantification. An alternative method for quantification in this setting is to obtain free-breathing phase-contrast imaging with an increased number of signal averages (minimum of 5) and using real-time free-breathing cines with motion correction for the volumetric acquisition, which has comparable accuracy to standard breath-held cine acquisitions. 16 Several early studies validated the diagnostic accuracy of CMR for quantifying MR severity against both echocardiography 17, 18 and invasive catheterization. 19 Despite positive early results, recent validation studies suggest that the agreement between 2D echocardiography and CMR might be modest, [20] [21] [22] although still a matter of debate. 23 In one study, 20 exact concordance between echo and CMR was seen in 50% only but increased to 91% when concordance was assessed within one grade of severity. Among those with discrepancy, there were more patients with functional MR (FMR), but there was no consistent overestimation of MR severity by either method. Among patients with moderate-to-severe primary MR, regurgitant volume assessed by 2D transthoracic echocardiography had poor agreement with MR volume measured by phase contrast velocity mapping on CMR. 21 In a prospective, multicenter trial, agreement between CMR and echocardiographic estimates of MR severity were modest in the overall group of patients evaluated (r=0.60) and particularly in the patients subsequently referred for surgery (r=0.40). 22 Inter-and intraobserver variability for quantification of MR volume has also been reported to be lower using CMR compared with transthoracic echocardiography, suggesting that the former may be superior for serial measurements. 24 CMR quantification of MR severity does seem to have better agreement with 3D compared with 2D echocardiographic methods. 25, 26 When the multiparametric approach for MR severity grading is used as the gold standard, CMR assessment of MR volume using the volumetric approach had the best accuracy (R=0.87) that was similar to 3D echocardiography (R=0.79) and superior to 2D echocardiography (R=0.60). 27 Ultimately, reproducibility and accuracy are important in the quantification of MR so as to enable appropriate downstream treatment and to identify those patients who are most likely to benefit from surgical intervention. Prospective studies have shown that CMR-based quantification of MR can more reliably predict outcomes after surgery. The degree of The Role of CT and MRI postsurgical LV reverse remodeling (assessed by the improvement in LV end-diastolic volume index) was recently shown to correlate strongly with CMR determined MR severity but not with echocardiography-determined MR severity. 22 In another study, CMR-derived calculations of MR volume and fraction were predictive of progression to symptoms or other indications for surgery. In that study, MR volume >55 mL and MR fraction >40% separated patients with primary MR who did or did not progress. Importantly, these parameters were predictive of outcomes independent of LV remodeling determined by MR quantification of LV volumes. 28 Interestingly, although the above CMR cutoffs were predictive of outcomes, Aplin et al 29 recently showed that among patients with severe MR and LV volume overload necessitating surgery by conventional guidelines (LV end-systolic diameter ≥40 mm), CMR-derived MR volumes and fractions corresponded to lower values (>40 mL and >30%, respectively) than previously thought. Therefore, more studies are needed to validate specific CMR thresholds of MR severity according to its type (primary versus secondary) and importantly its translation into outcomes. Nevertheless, CMR confirmation of MR severity should be considered in patients with suboptimal echo windows, in patients with discrepancy between symptoms and echocardiographic findings or when echocardiographic parameters for MR severity gradient are inconsistent if severity will influence decision making and timing of surgical or transcatheter intervention.
Cardiac MRI for the Assessment of Left Ventricular Remodeling
Current guidelines emphasize the importance of 2D echocardiographic measures of LV size and function as markers of LV remodeling that may necessitate surgery in patients with primary MR (LV ejection fraction <60% or LV end-systolic diameter ≥40 mm) or predict poor postoperative response (LV ejection fraction <30%). CMR, however, may be able to detect LV remodeling before any apparent change on 2D echocardiography. In patients with isolated degenerative MR, despite relatively preserved basal end-systolic dimensions, spherical mid to apical LV remodeling contributed to higher LV endsystolic volume than predicted by geometry-based calculations. 30 Similarly, in patients with at least moderate MR but without overt LV dysfunction, echocardiography significantly underestimates the degree of LV remodeling compared with CMR. 21 In addition, CMR can also quantify volumetric and functional changes in left atrial and pulmonary venous indexes with good reproducibility. These parameters may be important in the evaluation of asymptomatic patients with severe MR to determine when patients should be referred for early surgery. 29, 31 Taken together, it is important to highlight that CMR is accepted as the gold standard for noninvasive LV and RV size and systolic function. This makes CMR a useful and more accurate imaging tool in assessing the hemodynamic impact of both MR and tricuspid regurgitation (TR).
The presence of myocardial fibrosis (MF) has also been shown to allow for risk stratification in patients with VHD, irrespective of other clinical and functional parameters. 32 CMR is the gold-standard method for noninvasive evaluation and quantification of replacement MF. Traditional late-gadolinium enhancement imaging uses a T1-weighted segmented inversion-recovery sequence ≈8 to 10 minutes after gadolinium injection. The appropriate inversion time can be manually selected according to the Look-Locker pulse sequence or more frequently using an automated phase-sensitive inversion recovery sequence, which does not require an inversion time-mapping sequence. In addition, technological advances now allow for late-gadolinium enhancement imaging acquisition without the need for breath-hold with exquisite spatial resolution. 33 In primary MR, particularly for patients with MVP, there is emerging evidence that identification of MF could be associated with increased risk of cardiac arrhythmias and sudden cardiac death. The presence of papillary muscle delayed enhancement, in particular, has been shown ( Figure 1A ) to be associated with complex ventricular arrhythmias. 34 In a large autopsy study of patients with MVP, basal inferolateral scar ( Figure 1B and 1C) was associated with sudden cardiac death, suggesting a more malignant phenotype. 35 Moreover, patients with MVP often demonstrate mitral annular disjunction, where the mitral annular insertion is displaced toward the atrium rather than being at the junction of the left ventricular and atrial myocardial junction. This atrialization of the mitral annulus (MA) has been well described in echocardiographic and pathological literature. 36, 37 Importantly, mitral annular disjunction causes systolic curling and increases basal inferolateral myocardial stretch. The length of disjunction ( Figure 1D ) correlates with the extent of MF quantified by CMR. 38 Although preliminary, these data suggest an important role of CMR with late-gadolinium enhancement imaging for risk stratification in a selected subgroup of patients with primary MR.
For secondary ischemic MR, CMR can provide comprehensive assessment of adverse LV remodeling and infarct size, which can help predict which patients are at highest risk for increasing severity of ischemic MR. 39, 40 Recent technological advances in CMR, such as with the use of T1 mapping and extracellular volume fraction, allow for noninvasive quantification of diffuse interstitial MF, which histologically seems to be more prevalent than replacement MF. 41 A small single center study demonstrated that in asymptomatic patients with severe primary MR, extracellular volume correlated inversely with LV ejection fraction, LV longitudinal function, and peak Vo 2 max. Thus, it seems that diffuse MF may precede structural and functional changes taking place at the subclinical level. 42 Although MF findings in these patients are provocative, its role in the decision-making process and timing of interventions remains to be determined.
Potential Role of CT in Evaluating LV Remodeling and MR Severity
In patients with suboptimal echo windows or with contraindications to CMR (eg, implantable pacemaker/defibrillator or other metallic implants, claustrophobia, etc) in whom accurate quantification of ventricular volumes and systolic function is needed to decide on the need for valvular interventions, retrospectively-ECG-gated cardiac CT is a reasonable alternative. Multiphasic data are obtained throughout the cardiac cycle and despite its inferior temporal resolution compared with CMR, CT permits acquisition of a complete 3D data set with superior spatial resolution. Summation of planimetered short-axis or axial slices for volumetric analysis can be easily performed. A potential advantage of CT in this setting is the ability to reconstruct volumetric stacks in any of an infinite number of planes allowing accurate segmentation of basal slices aligned with the mitral and tricuspid annuli for LV and RV assessment, respectively. Normative values have traditionally been extrapolated from CMR but have also been reported for CT. 43 In addition to quantifying ventricular volumes, MR volume can also be calculated using the volumetric method (LV SV−RV SV) and has been shown to have good correlation with CMR. 44 Because of the multiplanar reformatting capabilities of 3D CT data sets, the inner contour of the anatomic MR orifice can also be manually traced and has been shown to correlate with echoderived effective regurgitant orifice area, 45, 46 although this is challenging for several reasons including the eccentric nature of MR, the varied points in the cardiac cycle it may occur, and the limited temporal resolution of CT. Overall, the place of CT here is limited to being an alternative test for patients with poor acoustic windows and a contraindication to CMR.
Cross-Sectional Imaging for the Determination of the Cause of Mitral Regurgitation
In primary degenerative MR, the mitral valve is intrinsically abnormal ranging from mild fibroelastic deficiency to frank Barlow disease. Secondary MR or FMR is traditionally defined as MR caused by regional or global LV dysfunction that results in failure of leaflet coaptation in the absence of a primary mitral valve disorder. Although not the initiating factor, adaptive changes including enlargement of the leaflets to increase the coaptation length and minimize the regurgitant orifice are known to occur in FMR. [47] [48] [49] Although echocardiography is the established gold standard method for evaluating the mechanism of MR, in particular using 3D echocardiographic methods, several recent studies have evaluated the growing role of CT and MRI for determining MR mechanism.
CMR for Determining the Mechanism of MR
The primary role of CMR in patients with MR, as mentioned before, is accurate quantification of MR severity and assessment of LV remodeling. Nevertheless, CMR can also be used to determine MR mechanism and has the advantage of permitting reconstruction of any 2D plane without the limitations of suboptimal echo windows. Geometric parameters of the mitral valve apparatus obtained from CMR have been shown to correlate with the particular mechanism of MR. Buchner et al 50 showed that CMR was able to discriminate the type of MR based on the regurgitant orifice geometry. Moreover, CMR has been shown to reliably characterize the MR jet in MVP compared with echo 51 and with surgical findings. 52 CMR is inferior to echo, however, in depicting certain anatomic details such as torn chordae and, compared with CT, is inferior for visualizing calcification of cardiovascular structures, which can be particularly important for transcatheter interventions.
CT for Characterizing the MV Apparatus and Cause of MR
CT provides a 3D data set that allows good to excellent visualization of anatomic details of the mitral valve and its apparatus including thickening of the mitral valve leaflets, annular, and leaflet calcification and has good agreement with echocardiography and surgery in diagnosing mitral valve abnormalities. 53 It can be used to reliably characterize MVP by cross-referencing long-axis views of the MV with short-axis views of the various scallops (A1-3, P1-3; Figure 2 ). 54 CT reliably detected MVP with sensitivity, specificity, positive predictive and negative predictive values of 96%, 93%, 93%, and 96%, respectively, when compared with echocardiography 55 but importantly should not be diagnosed on transverse axial imaging because of the saddle configuration of the MA. In primary MR, CT can also identify patients that may qualify for MitraClip implantation on the basis of confirming a central regurgitant jet at A2-P2 commissure; coaptation length ≥2 CT can also be used for geometric assessment of the mitral valve, annulus, and LV remodeling to help determine the mechanism of FMR. In 29 patients with significant FMR, CT was used to demonstrate that the maximum tenting height and tethering of the posterior mitral leaflet were located at the central and posteromedial levels. 56 In another study, CT was used to show that among patients with coronary artery disease, increased LV end-systolic volume is associated with inadequate approximation of the mitral tetrahedron during systole, which consequently leads to FMR. 57 FMR was reliably predicted by the interpapillary distance and distance from the anterior MA to the medial papillary muscle root.
Role of CT in the Evaluation of Patients Being Considered for TMVR
For patients with severe MR who are unable to undergo surgery, the scope of available transcatheter procedures continues to expand with devices available for the treatment of native valvular disease and in patients with failing bioprostheses. For native MR, the MitraClip device (Abbott Vascular) has been studied in randomized trials and is undergoing widespread clinical adoption. 58, 59 Implantation of aortic transcatheter heart valves (THV) has been performed in patients with degenerated surgical mitral bioprostheses 60, 61 and in failing annuloplasty rings. 62, 63 Similarly, these valves have been implanted in patients with calcified mitral valve disease in patients presenting with mitral stenosis. [64] [65] [66] In cases of concomitant prosthetic paravalvular regurgitation, implantation of Amplatzer Vascular Plug III and other occluding devices has also been reported. 67, 68 More recently, however, TMVR in noncalcified but severely incompetent native mitral valves has received considerable interest with several devices currently being investigated in human studies. These devices share common components including an atrial sealing skirt, nitinol selfexpanding frame, and bioprosthetic leaflets. The devices have been delivered both transapically and through a transseptal approach. They vary primarily with regard to their anchoring The presence of prolapse is determined by qualitative assessment in the 3-chamber long-axis plane performed while scrolling (yellow arrows) between the different scallops in the short-axis plane to determine which ones are involved. In this example, prolapse of the P2 scallop is demonstrated (*) in (B) and (E). The Role of CT and MRI mechanisms. 6 Preliminary reports are promising with regard to procedural feasibility and short-term success in treating high-risk patients with severe MR.
For the majority of transcatheter mitral procedures, echocardiography is the primary modality for intraprocedural planning including 2D and 3D transesophageal echocardiography with cross-sectional imaging having no defined role in the intraprocedural setting at this stage. For preprocedural imaging, echocardiography also has a role with regard to screening patients and identifying those with favorable anatomic features for Mitraclip implantation 5 Although 3D assessment of the MA by CMR is feasible, 69 most of the planning of TMVR procedures is currently based on CT.
The role of CT in planning TMVR procedures is being increasingly reported with early integration of this imaging modality observed. This is likely because of the complex 3D structure of the MA and the need for high spatial-resolution imaging to properly define pathoanatomical considerations that are relevant to device-specific therapies. Cardiac CT acquisition in this setting requires a multiphasic (retrospectively-ECG gated) data set given the dynamic changes in the MA that have been reported previously 70 and reconstruction of thin slices (<1 mm) at all phases of the cardiac cycle. Broadly, the areas where CT may provide important information include: (1) determining MA size and geometry; (2) characterizing the MA landing zone; (3) predicting left ventricular outflow tract (LVOT) obstruction risk; (4) predicting fluoroscopic angles that are coplanar with the MA, and (5) access planning. The following discussion will focus primarily on the role of CT in planning TMVR procedures.
Determining Mitral Annulus Size and Geometry
Similar to transcatheter aortic valve replacement (TAVR) where CT-based preprocedural imaging has optimized annular sizing and device selection leading to reduced post-TAVR complications, TMVR has used CT for preprocedure annular sizing. The complex anatomy of the annulus requires a high-spatial resolution 3D imaging modality for optimal evaluation of annular dimensions and geometry. CT is best suited for this purpose and has been shown to accurately size the MA in animal studies investigating mitral annuloplasty rings. 71 To appropriately size the MA for the purpose of TMVR, however, an understanding of MA geometry, and, in particular, an understanding of the interaction between the MA and LVOT, is essential. Importantly, unlike the aortic annulus, the mitral valve apparatus is comprised of more than the left atrial and LV plane, but it includes the annulus, leaflets, chordae, and papillary muscles. The MA has a complex, saddle-shaped 3-dimensional geometry (Figure 3) . It consists of an anterior horn that is continuous with the aortic valve anteriorly (aorto-mitral continuity) and a posterior horn that is formed by the insertion of the posterior mitral leaflet at the atrio-ventricular junction posteriorly. The nadirs of the saddle are located near the fibrous trigones, which are defined as the regions of collagenous thickening at the ends of the aorto-mitral curtain. The medial fibrous trigone is continuous with the membranous interventricular septum. It is important to note that the anterior horn of the MA encroaches on the LVOT, and therefore, inclusion of this component in sizing of the annulus will lead to device encroachment into the LVOT and potentially fatal LVOT obstruction Dedicated postprocessing CT software packages allow 3D segmentation of the annulus and exclusion of the anterior horn for annular assessment using a truncated or so-called D-shaped concept of the MA. This is achieved by manual segmentation that involves stepwise placement of seeding points in a facilitated fashion every 22° along the 3D contour of the MA followed by truncation of the anterior horn at the level of the fibrous trigones to yield a D-shaped annulus. For the purpose of measuring the MA dimensions, a 2D projection of the MA is extrapolated using the least-squares method. Several parameters have been now been reported that are of potential importance in sizing the annulus prior to TMVR (Figure 4) . These include the projected 2D area, perimeter, intercommissural, septal-lateral, and intertrigonal (trigonetrigone) distances. The perimeter is the sum of the posterior 2D perimeter and trigone-trigone distance. Mean diameter obtained from the average of the septal-lateral and intercommissural distances has been proposed as a potentially simple index of the effective MA size and showed better correlation to the MA area than both intercommissural and septal-lateral distance. 72 While the above parameters have been shown to be reproducible [72] [73] [74] this is diminished in the setting of significant mitral annular calcification (MAC). 72 Additionally, the presence of caseous MAC can affect accurate annular segmentation as it is often difficult to discriminate caseous MAC from the blood pool. Another important consideration is the common observation of MA disjunction in patients with MVP as described above. Apart from being clearly identifiable on CT this anatomic finding creates issues regarding segmentation of the annular geometry particularly posteriorly. This potentially can affect annular sizing and therefore device selection. Intuitively, the appropriate annular size should be used in these patients by segmenting the annulus at a level that corresponds to the probable position of the device however further study to clarify the impact of disjunction on the landing zone and biomechanical hinge of the device is required.
We have previously reported normative values for D-shaped mitral annular dimensions in patients without significant cardiac disease as well as in patients with moderate to severe MR because of either FMR or degenerative mitral valve disease/MVP. In subjects without mitral valve disease there is a wide interindividual variation in annular dimensions as well as an independent positive association between MA size and LV and left atrial (LA) size. Interestingly, mitral annuli are larger in men than women but when corrected for body surface area these differences become insignificant. In patients with MR, annular dimensions are significantly larger, particularly in those with MVP, and annular geometry is distorted with septal-lateral expansion. Similar to previous studies using conventional methods for quantifying annular size, MA area was 18% larger in patients with MVP compared with FMR in our study. 75 Although most reports describing the early TMVR experience have used CT for annular sizing, in cases when CT cannot provide adequate image quality or CT is contraindicated, 3D echocardiography is a potential alternative test. Previous studies comparing 3D echocardiography and CT have shown good correlation with regard to conventional measures of MA geometry. 26 More recently, Mak et al 76 showed that 3D transesophageal echocardiography can be used for D-shaped mitral annular segmentation without systematic differences in annular dimensions. Adequate imaging training for acquisition and postprocessing is necessary to yield accurate information in the procedural planning of TMVR.
Characterizing the Mitral Annular Landing Zone
Landing zone characteristics and remodeling of the mitral apparatus and ventricle in MR patients are important for preprocedural TMVR planning, particularly given the different devices have their own anchoring mechanisms for capture and stability. Moreover, it is important to identify certain features that may preclude patients from TMVR. These anatomic characteristics are uniquely identifiable and characterizable on CT and are discussed below.
MR Mechanism and the Presence of a Posterior Basal Shelf
In TMVR, an important consideration in FMR patients is the nature of atrio-ventricular remodeling as this has important implications with regard to the anchoring mechanisms of devices currently under investigation. We have recently evaluated MA geometry in relation to LA and LV remodeling among patients with moderate to severe FMR and found that while FMR was associated with significantly enlarged LV size, the annular size in FMR patients is more closely associated with LA size. 75 This may be because of the modest variation in ventricular size between FMR patients given that the development of FMR is dependent on LV dilatation. Importantly however, it appears that as the LV dilates the normally linear relationship between the LA and LV myocardium is disturbed with the development of a posterior shelf. This shelf size is dependent on many factors but is commonly larger in the setting of LV dilatation related to myocardial infarction. Importantly, this shelf may be dynamic with significant changes in its size and configuration and may disappear in systole. The identification and sizing of the posterior myocardial shelf in systole and diastole is important as many of the investigational TMVR devices rely on this shelf to allow capture and positioning ( Figure 5) .
In primary MR, although the mechanism of MR does not relate to ventricular remodeling, we have previously shown that annular geometry does relate directly to both LA and LV size. 75 Importantly, these patients do not appear to develop discordant LA and LV remodeling resulting in a lack of the same posterior shelf that is observed in FMR.
Mitral Annular Calcification
CT can also identify and characterize MAC that may be important for transcatheter therapies. MAC occurs in a significant proportion of elderly patients with severe MR requiring surgical intervention. 77 The mechanism of MAC has been historically thought of as an age-related degenerative disorder; however, other mechanisms may also be important including processes similar to atherosclerosis-related calcification such as coronary artery disease 78 but also calcium-phosphorous metabolism as is seen in patients with chronic kidney disease. 79 Although MAC can be visualized as an ill-defined echodensity on echo, its extent and location are best characterized on cardiac CT. In a recent study using CT, the location and extent of MAC was evaluated in 318 patients aged ≥65 years who underwent clinically indicated CT scans. MAC was most common in the posterior MA, especially its middle (P2) segment. 80 For the anterior MA, the medial (A3) segment was most often affected. In patients being referred for TAVR, CT can provide evaluation and quantification of MA calcium volume, which correlates with the mitral valve area and severity of mitral stenosis. 81 In the setting of aortic THV implantation in calcific mitral valve disease, the presence of MAC is thought to promote device anchoring. This is only the case, however, when the calcium assumes a homogenous and circumferential configuration in the annulus. Himbert et al 82 reported aortic THV implantation in 4 patients with calcific mitral stenosis via transseptal implantation. They describe grade 3+ MR in one patient attributed to a protruding nodular calcification that improved to grade 2+ after postdilatation. Indeed, they did not accept many patients for TMVR because MAC was isolated to the posterolateral segments of the annulus, which is the more commonly observed pattern. The importance of the amount and distribution of calcification in anchoring aortic THV devices was also suggested by Nguyen et al. 83 Among 18 patients that underwent implantation of a balloon-expandable aortic THV (Sapien 3, Edwards Lifesciences, Irvine, CA), 2 developed late device migration into the LA resulting in significant paravalvular leak. Similar device migration was also described in two patients by Bapat et al. 84 These reports highlight that anchoring of the THV in patients with MAC may not be as effective as in those with a mitral valve bioprosthesis or ring, and importantly, this depends on the extent and distribution of calcification around the MA. CT characterization of MAC is therefore likely to play an important role in predicting the likelihood of both immediate device capture as well as the risk of long-term device migration. The identification of circular and homogenous calcification of the MA seems to be important in these patients. Recent multicenter registry data of patients with severe MAC undergoing balloon expandable valves demonstrate that despite its procedural feasibility, the associated mortality is significant (30% all-cause mortality within 30 days). 85 Unlike the use of aortic THV for calcific mitral stenosis, TMVR devices for severe MR have their own anchoring mechanisms that are not reliant on the presence of MAC. Early feasibility studies have tended to exclude patients with severe MAC as it is conceivable that severe and bulky MAC will interfere with the apposition of the self-expandable TMVR systems, potentially creating a substrate for paravalvular leak. CT therefore has an important role in screening patients with asymmetrical and in particular bulky, protruding calcification that may interfere with device apposition and preclude them from TMVR ( Figure 6 ).
Basal LV Cavity
Characterization of the basal LV cavity size is also important for patients undergoing TMVR to ensure there are adequate dimensions for housing the mitral device. While this is especially important in patients with small LV cavities as may be seen in elderly women, it is less problematic in patients with FMR. Theriault-Lauzier et al 86 recently evaluated the size of basal LV cavity, which they refer to as the obstacle free zone using CT in FMR patients and showed that the diameter of this zone is >20 mm on average in patients with FMR and varies by <1 mm throughout the cardiac cycle. Nevertheless, CT can provide patient specific anatomic information about basal LV cavity size as well as characterize the location and size of papillary muscles to ensure there is adequate room for the TMVR device. In addition, other anatomic features such as leaflet length can also be evaluated on CT and has particular implications for devices that rely on attachment to the leaflets as part of their capture mechanism.
Predicting LVOT Obstruction Risk
It was recognized early in the development of TMVR that LVOT obstruction is a significant risk associated with device implantation given the proximity to the LVOT and potential for device encroachment. The mechanism of LVOT obstruction after device implantation is likely to be because of both fixed obstruction that occurs as a result of narrowing of the LVOT; and dynamic LVOT obstruction because of systolic anterior motion of the native anterior mitral leaflet, which is displaced into the LVOT by the TMVR device. Two primary anatomic factors beyond device size, design and canting, have been reported as potential markers of increased LVOT obstruction risk including (1) aorto-mitral angulation and (2) neo-LVOT area. Both of these can be assessed on preprocedure cardiac CT.
The first marker of risk identified was a steep aortomitral angle. This angle is defined as the angle formed by the intersection of the MA trajectory line and LVOT long axis (Figure 7) . LVOT obstruction risk is considered to be directly related to aorto-mitral angle value with the highest risk being at 90°, that is, when the LVOT and MA trajectory are perpendicular to each other. Conversely, the lowest risk would be in the theoretical situation when the two are parallel to each other. Aorto-mitral angle can be easily obtained from CT data, is reproducible 74 and higher in systole compared with diastole. Second, reduced area of the neo-LVOT has also been proposed as a marker of increased LVOT obstruction risk (Figure 8 ). After the TMVR device is implanted, the residual area of the LVOT is decreased as the anterior mitral leaflet is displaced into the LVOT by the covered device. The area formed between the anterior leaflet, device and interventricular septum can be narrowed and is referred to as the neo-LVOT. Although cutoffs for defining increased risk are not known for TMVR devices, extrapolation from the hypertrophic cardiomyopathy literature has been suggested and an area <2.0 cm2 has been proposed as an arbitrary cutoff. 6, 87 Further studies to more precisely define the appropriate The Role of CT and MRI cutoff and the importance of dynamic functional imaging simulation are needed.
Additional factors may also contribute to LVOT obstruction risk, some of which are identifiable on preprocedure CT. For example, the identification of bulky calcifications on the anterior mitral valve leaflet, which may be displaced into the LVOT by the implanted device is an important finding easily identifiable on CT. Moreover, the presence of a basal septal bulge (sigmoid septum) is also important as this can increase the risk of postimplantation LVOT obstruction by further narrowing the neo-LVOT, especially in patients with a small LV cavity.
Predicting a Coplanar Mitral Annular Plane
During TMVR, accurate imaging of the mitral annular plane is important for ensuring coaxial deployment. Similar to TAVR, CT has been shown to help predict a coplanar angle for coaxial deployment of the TMVR device. 88 More recently, the left circumflex-right coronary artery plane was shown to have a close relationship to the mitral annular plane and was suggested as a potential method for ensuring coaxial deployment.
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TMVR Access Planning Using CT
CT may also have a role in determining the appropriate transapical access point that will ensure coaxial deployment of the TMVR device. We have evaluated the role of CT in this setting and shown that the location of the orthogonal LV access point exhibits interindividual variability and commonly does not correspond to the site of the LV apex but rather to the apical anterolateral or anterior segments of the LV (submitted data).
Cross-Sectional Imaging in Tricuspid Valve Disease
The tricuspid valve is similar to the mitral valve in that it is a complex consisting of three leaflets (anterior, posterior, and septal), chordae tendinae, 3 discrete papillary muscles (septal, posterior, and anterior), the fibrous tricuspid annulus, and extends to include the right atrial (RA) and RV myocardium. Each of the 3 leaflets has distinguishing anatomic features. The anterior leaflet is the largest and the posterior leaflet displays multiple scallops. The septal leaflet originates medially from the tricuspid annulus itself immediately above the interventricular septum. The orifice of the tricuspid valve is described as semilunar 90 and is more triangular compared with the mitral valve orifice. The tricuspid valve orifice and annulus are substantially larger than the mitral valve orifice and annulus. The tricuspid valve and annulus are also dynamic structures, with conformational changes observed throughout the cardiac cycle and according to changes in loading conditions. TR is the most common form of right-sided VHD and its prevalence is likely underestimated. 90 Whereas trivial or mild TR are frequently observed and well tolerated in normal individuals, significant TR is associated with volume overload and causes progressive chamber dilation giving rise to atrial and ventricular arrhythmias, and increased morbidity and mortality if underlying VHD is left untreated. Similar to MR, TR can be related to either primary anatomic valvular problems or, more commonly, secondary to remodeling changes of the right atrium (RA) or RV. This is commonly because of tricuspid annular dilation (either secondary to RA or RV dilation) or because of tethering/tenting from RV dilation and papillary muscle displacement secondary to free wall dilation. 91, 92 Similar to what is described for FMR, right-sided remodeling changes cause papillary muscle displacement with flattening of the tricuspid annulus and leaflet tenting, all of which are linked to the chronicity and severity of functional TR. Given 
CMR for the Evaluation of Tricuspid Disease
Given its excellent spatial resolution, CMR can be additive to 3D echocardiography for both anatomic and functional analysis of the tricuspid valve, annulus and right-sided heart chambers.
Evaluation of Right-Sided Chambers on CMR
Comprehensive evaluation of right-sided chambers can be performed using CMR without the need for radiation or iodinated contrast. Several prescription planes can be obtained for dedicated imaging of the RV as shown in Figure 9A through 9C and Movie I in the Data Supplement. This is a particular strength of CMR over 2D echocardiography, which is challenging and requires multiple windows. Although 3D echocardiography can substantially improve the limitations of standard 2D evaluation of the RV, it still requires optimal echocardiographic windows for adequate data acquisition and analysis. This can be particularly challenging in obese patients or in those with lung disease, breast implants, etc. CMR quantification of RV size and function usually involves dedicated acquisition of a stack of short-axis cine images (10 mm slice thickness, gaps varying between 0 and 4 mm) where semiautomated endocardial border segmentation is performed for calculation of the end-systolic and end-diastolic volumes, and RV ejection fraction ( Figure 9D ). In the presence of pulmonary hypertension, associated RV hypertrophy occurs and calculation of RV mass index can also be performed by CMR. In patients with irregular heart rate free-breathing real-time cine acquisitions can be attempted and still provide quantitative information ( Figure 9E ).
Evaluation of the Tricuspid Valve and Annulus on CMR
Apart from volumetric analysis, CMR can also be used to evaluate tricuspid valve leaflet morphology ( Figure 10A ) although this can be challenging given the thin nature of the leaflets and through-plane motion from the tricuspid annulus. Measurement of the tricuspid annulus by CMR can be performed using breath-held cine images from several long axis views and prescription planes (Figures 10B through  10E) . 94 This allows for measurements to be obtained at both and severely reduced in example (E) and (F; 0.5 cm2) corresponding to increasingly higher risk of LVOT obstruction after TMVR. The Role of CT and MRI systole and diastole but can be challenging in patients with atrial fibrillation or frequent ectopics. An alternative method is to use commercially available navigator-echo methods, like noncontrast ECG-gated steady-state free precession magnetic resonance angiography, which synchronizes respiratory and cardiac gating allowing 3D data set acquisitions without the need for intravenous contrast. 95 Multiplanar reconstructions for detailed anatomic evaluation can be performed offline with excellent spatial resolution ( Figure 11 ). Furthermore, two data set acquisitions (systolic and diastolic) can be obtained; however, this can be time consuming as each acquisition takes 7 to 10 minutes on average. Importantly, this technique can be used in patients with cardiac arrhythmias, and in those unable to perform serial breath-holds allowing for reliable measurements comparable to CT. 96 At the present time there is no commercially available software for tracking of the tricuspid annulus throughout the cardiac cycle using cine CMR data sets.
Quantification of TR Severity by CMR
Quantification of TR by CMR is commonly performed using the indirect method by calculating the tricuspid regurgitant volume as the difference between the planimetered RV stroke volume and forward pulmonic flow volume using breath-held phase-contrast imaging, similar to the assessment of MR described above. The TR fraction is calculated as (TR volume/ RV stroke volume)×100%. The cutoffs to determine the severity of TR have not been established but in general, a tricuspid regurgitant fraction ≥40% is considered to be hemodynamically significant. Cardiac arrhythmias, which can be seen in patients with MR/TR, can affect study image quality, however, making it difficult for precise quantification of TR. An alternative method for quantification in this setting is to consider obtaining free-breathing phase-contrast imaging with increased number of signal averages (minimum of 3). In addition, TR may be related to the presence of leads from implantable cardiac devices such as pacemakers or defibrillators most of which are not MRI conditional, and therefore not safe for scanning even at lower magnetic field strength (ie, 1.5 T). In addition, local expertise is required for performing CMR studies in such patients with implantable cardiac devices. Another method for assessing TR severity is the direct visualization and measurement of the effective regurgitant orifice area, but this is not always feasible ( Figure 10A ).
CMR to Guide the Timing of Tricuspid Valve Surgery and Predict Outcomes
Data are limited on the potential role of CMR in patients being evaluated for tricuspid valve surgery. In a small series of 31 patients with severe functional TR, CMR reliably tracked RV remodeling, which can be helpful to determine the timing of tricuspid valve surgery. Importantly, CMR after effective tricuspid valve surgery demonstrated hemodynamic improvement in forward LV stroke volume and cardiac index. 97 The same group also recently showed that in patients with severe functional TR, volumetric quantification of RV end-systolic volume index and RV ejection fraction by CMR are important to predict all-cause and cardiac mortality. 98 Because all patients Figure 11 . Three-dimensional whole heart cardiac magnetic resonance data set with multiplanar reformatting obtained for assessment of tricuspid annular size and geometry. 
Role of CT in Planning Transcatheter Tricuspid Interventions
The complex configuration but more importantly the large size of the tricuspid annulus particularly in the setting of TR makes the prospects of a transcatheter valve replacement highly challenging. As a result, the focus to date has been on spacer devices, which reduce the regurgitant orifice area or percutaneous annuloplasty devices. Caval valve implantation devices that reduce backward flow in patients with severe TR are also undergoing investigation. 99 The role of CT imaging to help with patient screening and procedural planning of transcatheter tricuspid valve interventions is less well established than in the mitral space. A recently introduced spacer device (Forma, Edwards Lifesciences) has demonstrated promising results in early reports. 100 Among 7 patients with severe TR, device implantation resulted in a significant reduction in TR severity to moderate in 3 and mild in 4 patients; as well as improvement in New York Heart Association class in most patients at 30-day follow-up. Echocardiography and fluoroscopy guide the device deployment however CT is also used to measure tricuspid annulus dimensions, distance from the tricuspid annulus to the RV apex, and RV size ( Figure 12 ). Of note, similar measurements can be obtained with CMR using free-breathing, noncontrast 3D whole-heart steady-state free precession sequence. In addition, preimplant CT plays an important role in defining fluoroscopic angles of coplanarity to the tricuspid annulus to help guide the procedure. CT was also reportedly used to assess the size of the subclavian and axillary veins, which are used to deliver the sheath and device.
The Mitralign device (Mitralign, Inc, Tewksbury, MA), which was originally designed to plicate the mitral valve annulus, has shown promise in treating functional TR as well. The early experiences with this device 101 did not rely on significant CT integration however cardiac CT can easily define individual variations in tricuspid anatomy and also localize the right coronary artery to help identify patients at potential risk for coronary artery injury. Similarly, the TriCinch device (4Tech Cardio, Galway, Ireland) is a percutaneous annuloplasty device undergoing investigation for functional TR that is comprised of a stainless steel corkscrew that is fixed in the anteroposterior tricuspid annulus and connected via a Dacron band to a self-expanding nitinol stent that is deployed in the inferior vena cava. The device remodels the anteroposterior annulus by the tension generated through pulling of the corkscrew toward the inferior vena cava, resulting in a reduction of septal-lateral dimensions. Based on first-in-man reports, CT in this study is used for procedural planning to identify a safe anchoring area for the device at the anterior tricuspid annulus between the right coronary artery and anterior leaflet hingepoint. As such, impingement or injury of the right coronary artery can be a complication of these new procedures. Of note, the minimal distance to the tricuspid annulus for transcatheter annuloplasty devices has not been determined. Moreover, CT is used to ensure the correct IVC stent size is selected to guarantee appropriate oversizing in the hepatic region of the IVC. 102 A comprehensive anatomic evaluation of the spatial relationship between the tricuspid valve annulus and right coronary artery using CT in patients being considered for TAVR was recently published. The cohort was divided according to the severity of baseline functional TR (<3+ versus ≥3+). Patients with ≥3+ TR had, in addition to the expected more pronounced tricuspid annulus and right-sided chamber remodeling, very capacious RA-inferior vena cava junction (mean area 674±193 mm 2 ) and short distance between RA-inferior vena cava junction and first hepatic vein suggesting the need for a customized caval valve prosthesis. They also noted that ≈40% of patients with ≥3+ TR had the right coronary artery coursing ≤ 2.0 mm to the annulus which could suggest as less favorable anatomy for transcatheter tricuspid valve interventions given the risk of right coronary artery injury, 103 although prospective validation of this threshold is necessary.
Conclusions
While echocardiography remains the primary imaging modality for the evaluation of patients undergoing transcatheter procedures for the treatment of mitral and tricuspid valve disease, cross-sectional imaging is being increasingly recognized as a tool that can provide additive information. CMR is particularly useful for accurately quantifying MR severity and determining the extent of ventricular remodeling to help identify patients that are most likely to benefit from intervention. CT provides 3-dimensional data with high spatial resolution that can accurately characterize the mitral valve apparatus and provides useful information for TMVR planning with regards to annular and device sizing, characterization of the landing zone, predicting LVOT obstruction risk and access planning. Although less studied, cross-sectional imaging seems to have a similar role in the evaluation of right-sided valvular disease with CMR providing useful information regarding the haemodynamic severity of TR and extent of RV remodeling; while CT provides important morphological data and is likely to help guide device-specific planning for transcatheter tricuspid therapies.
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